Navigation Links
Targeted Nanoparticles Offer Promise in the Battle Against Cancer
Date:10/16/2007

RESEARCH TRIANGLE PARK, N.C., Oct. 16 /PRNewswire/ -- Liquidia Technologies announces a series of speaking engagements by company founder and University of North Carolina-Chapel Hill professor, Joseph DeSimone. At a series of events this fall, Dr. DeSimone will discuss drug delivery applications of the PRINT(TM) platform and his ongoing research in cancer therapeutics.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060614/CLW002LOGO )

-- Prostate Cancer Foundation Scientific Retreat - October 12, Lake Tahoe,

NV

-- NCI Nanotechnology Alliance Investigators Meeting - October 16, Chapel

Hill, NC

-- Williamsburg BioProcessing Foundation Conference - November 1, Austin,

TX

-- Nanomedicine & Drug Delivery Symposium - November 2, Boston, MA

-- Nanotechnology in Biology and Medicine Conference - November 5,

Charlotte, NC

-- American Chemical Society Workshop - November 7, Lake Tahoe, NV

"These engagements are a clear indication of the widespread commercial and scientific interest in the PRINT(TM) technology platform, developed by Dr. DeSimone and his colleagues," says Dr. Bill Weiser, General Manager of Pharmaceuticals at Liquidia. "The PRINT platform enables Liquidia and its licensees to develop novel engineered drug therapies based on precise nanoparticle design and scalable manufacturing capabilities."

DeSimone and researchers at Liquidia and UNC are exploring applications for the PRINT platform in a number of areas including delivery of oligonucleotides and cancer therapeutics. In collaboration with the National Cancer Institute (NCI), DeSimone is examining the effect of particle size and shape on cellular uptake, and the ability of specific ligands on the surface of a nanocarrier to promote cellular targeting.

During the 2007 Controlled Release Society Meeting, DeSimone presented data from a melanoma mouse model, in which 200 nm PRINT particles with aVb3 ligands successfully targeted the angiogenic tumor vasculature. Based on further pre-clinical studies, a PRINT-based cancer therapeutic is expected to enter clinical trials in 2008.

About Liquidia

Liquidia Technologies Inc. is an innovative nanotechnology company that designs, develops, and manufactures precisely engineered particles and films for a wide variety of life and materials science applications. Liquidia's proprietary PRINT(TM) platform is unique in its ability to replicate and produce nanoscale features with absolute control over particle size, shape, and composition. The company was founded in 2004 on the discoveries of Professor Joseph DeSimone at the University of North Carolina, Chapel Hill and is located in Research Triangle Park, North Carolina. For additional information, please visit http://www.liquidia.com.


'/>"/>
SOURCE Liquidia Technologies
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
3. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
4. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
7. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
9. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
10. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
11. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017  This report analyzes the worldwide markets for ... Products: Intermediates, Analytical, and Others. The End ... and Agrochemicals. The report provides separate comprehensive analytics for ... Europe , and Rest of World. Annual estimates ... 2022. Also, a six-year historic analysis is provided for ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis and ... global Urinary Incontinence market. The research answers the following questions: ... for Urinary Incontinence and their clinical attributes? How are they positioned ...
(Date:2/23/2017)... MINNEAPOLIS , Feb. 23, 2017  Cogentix Medical, ... manufactures and markets innovative proprietary products for the urology ... and fiscal year ended December 31, 2016 before the ... The Company will host a conference call and ... on Thursday, March 9, 2017 at 11:00 a.m. Eastern ...
Breaking Medicine Technology:
(Date:2/24/2017)... Houston, TX (PRWEB) , ... February 24, 2017 ... ... now offering promotions on tooth replacement options at his office, Antoine Dental Center. ... dental implants for $18,499. Some restrictions may apply, but patients can learn more ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic variants implicated ... to eight genes that may explain why susceptibility to one of the disorders could ... study published today in the journal npj Schizophrenia. , “There is a wealth ...
(Date:2/24/2017)... New York, NY (PRWEB) , ... February 24, 2017 , ... ... urges: “Security needs to be a top priority because it’s not if you will ... in online safety, especially when it comes to digital health care. , Improvements in ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... concerning this present generation. Yisrayl makes an astounding statement when he says that ... explains that the Bible details the current times so plainly that anyone should be ...
Breaking Medicine News(10 mins):